Novartis acquires The Medicines Company and inclisiran

Novartis announced that it has entered into an agreement and plan of merger with The Medicines Company to acquire the US-based biopharmaceutical company for $85.00 per share in cash, valuing the company at approximately $9.7 billion on a fully diluted equity basis. The offer price represents a premium of approximately 41% over The Medicines Company�s 30-day (to November 22, 2019) volume weighted average price of $60.33 and approximately 24% premium over The Medicines Company�s closing share price of $ 68.55 on November 22, 2019 which represented a fully diluted equity value of approximately $7.7 billion when including the impact of outstanding stock options and convertible debt. The transaction has been unanimously approved by the Boards of Directors of both companies.The Medicines Company recently announced data from its comprehensive clinical program consisting of three Phase III trials (ORION-9, 10 and 11) for inclisiran involving over 3,600 high-risk patients with ASCVD(atherosclerotic cardiovascular disease ) and FH ( familial hypercholesterolemia ). In all trials, inclisiran demonstrated potent and durable LDL-C reduction with an excellent safety and tolerability profile.